Prognostic factors for thyroid cancer based on glucose metabolism

2019 Fiscal Year Final Research Report

• Project/Area Number: 16K11231
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Otorhinolaryngology
• Research Institution: Osaka City General Hospital (2017-2019); Osaka University (2016)
• Principal Investigator: Hanamoto Atsushi 地方独立行政法人大阪市民病院機構大阪市立総合医療センター(臨床研究センター), 臨床研究センター, 医長 (20625917)
• Project Period (FY): 2016-10-21 – 2020-03-31
• Keywords: 甲状腺癌 / FDG-PET

Outline of Final Research Achievements

We investigated glucose metabolism as a prognostic factor for thyroid cancer. First, we examined FDG-PET, which is currently covered by insurance as a glucose metabolism test. These results showed that preoperative FDG-PET with large SUVmax, which indicates the degree of accumulation, and large tumor metabolic volume had a poor prognosis. As a further study, immunostaining of the excised specimen was performed. Glucose Transporter 1, Lactate Dehydrogenase A, Monocarboxylate Transporter 4, Fatty acid synthetase and Ki-67 were examined, but no significant difference in the degree of staining was observed in the degree of accumulation.

Free Research Field

頭頸部腫瘍

Academic Significance and Societal Importance of the Research Achievements

甲状腺癌はハイリスク群とローリスク群に分けられ、ローリスク群は甲状腺葉切除＋D1郭清、ハイリスク群は甲状腺全摘＋頸部郭清＋ヨード治療が推奨されている。しかし、両群ともに該当しない症例も多くあり、治療指針に関しては各施設にゆだねられている。この両群ともに該当しない症例をさらに細分化して、より正確な個別化治療ができることが望まれる。今回の研究でのFDGの集積の程度で更なる治療法の細分化ができる可能性がある。